Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib Drug-Drug Interaction Study With Itraconazole and Rifampin
NCT07374224Phase 1Recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rocbrutinib in B-cell malignancy, sponsored by Lupeng Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
rocbrutinib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07374224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374224.